ClinicalTrials.gg
CompletedNCT07155668Updated Jun 25, 2026

A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

A Phase 3 interventional study of VRDN-003 and Autoinjector in Thyroid Eye Disease, sponsored by Viridian Therapeutics, Inc.. Completed at 13 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Viridian Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies in Graves Ophthalmopathy with a site in United States — 12 open to participants now, 18 under way, 8 of them phase 3. Graves Ophthalmopathy · United States.

Enrollment
22nd of 47
87 · median 84
Started
2025
with 2 others
Phase 3
21 of 53
3 open now
Registered
43rd of 53
by date
Lead sponsor
9 of 53
Viridian Therapeutics, Inc.

Among the 53 studies in Graves Ophthalmopathy with a site in United States, this one is the 22nd largest by enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2025, is one of 21 in phase 3, and was the 43rd registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

12 of the 53 studies in Graves Ophthalmopathy with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Graves Ophthalmopathy with a site in United States, or all of them as a file.
02

Study summary

This is a clinical trial assessing the safety, tolerability and pharmacokinetics (PK) of an investigational drug, VRDN-003, in participants with TED (Thyroid Eye Disease)

Read the detailed description

This is a randomized (meaning participants will be assigned to study arms by chance), open-label (meaning study doctor, participant and the sponsor will know which study arm participant is assigned to), parallel-group study that will enroll participants with TED of any duration. The key objectives of this study are to determine if VRDN-003 is safe and tolerable and to see how the body reacts to VRDN-003 when administered as a series of subcutaneous (SC) injections every 4 weeks or every 8 weeks in participants with TED either via autoinjector or via vial and syringe.

03

Conditions studied

  • Thyroid Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Have a clinical diagnosis of TED with or without proptosis, with any CAS (0-7) and in the opinion of the Investigator may benefit from VRDN-003
  • Not require immediate ophthalmological or orbital surgery in the study eye for any reason
  • Must agree to use highly effective as specified in the protocol
  • Female TED participants must have a negative serum pregnancy test at screening

Key Exclusion Criteria:

  • Must not have received prior treatment with another anti-IGF-1R therapy
  • Must not have received systemic for any condition, including TED, or selenium within 2 weeks prior to first dose.
  • Must not have received other drugs for any condition, including TED, or any other therapy for TED, within 12 weeks prior to first dose
  • Must not have received an agent/device for any condition, including TED, within 8 weeks or longer (depending on the type of agent/device) prior to first dose
  • Must not have received radioactive iodine (RAI) treatment within 8 weeks prior to first dose
  • Must not have had previous orbital irradiation or decompression surgery for TED to the study eye's orbit
  • Must not have a pre-existing ophthalmic condition in the study eye which in the study doctor's opinion, would interfere with interpretation of study results
  • Must not have abnormal hearing test before first dose or history of ear conditions considered significant by study doctor
  • Must not have a history of inflammatory bowel disease
  • Female TED participants must not be pregnant or breastfeeding
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    VRDN-003 every 4 weeks using autoinjector

    6 subcutaneous administrations of VRDN-003 \[1 loading dose of 600mg and 5 doses of 300mg\]

    Drug: VRDN-003 · Device: Autoinjector

  • Experimental
    VRDN-003 every 8 weeks using autoinjector

    3 subcutaneous administrations of VRDN-003 \[1 loading dose of 600mg and 2 doses of 300mg\]

    Drug: VRDN-003 · Device: Autoinjector

  • Experimental
    VRDN-003 every 8 weeks using vial and syringe

    3 subcutaneous administrations of VRDN-003 \[1 loading dose of 600mg and 2 doses of 300mg\]

    Drug: VRDN-003

Interventions

  • VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).

  • DeviceAutoinjector

    The autoinjector is a single-dose, disposable, ready-to-use delivery device

06

What researchers measure

Primary outcomes

  1. Treatment Emergent Adverse Event (TEAE) incidence rate

    Treatment Emergent Adverse Event (TEAE) incidence rate

    Time frame: Through Week 24

Secondary outcomes

  1. Pharmacokinetic outcome measures

    Time of maximum serum concentration (Tmax) of VRDN-003

    Time frame: Through Week 24

  2. Pharmacokinetic outcome measures

    Maximum serum concentration (Cmax) of VRDN-003

    Time frame: Through Week 24

07

Study locations

13 sites
  • United Medical Research Institute
    Inglewood, California 90301, United States
  • C&A Clinical Trials Corp
    Cape Coral, Florida 33990, United States
  • Ilumina Medical Research
    Kissimmee, Florida 34744, United States
  • Med-Care Research
    Miami, Florida 33125, United States
  • Continental Clinical Research, llc
    Miami, Florida 33144, United States
  • Hype Clinical Research, LLC
    Miami, Florida 33145, United States
  • Advanced Quality Medical Research, LLC
    Orland Park, Illinois 60462, United States
  • Ophthalmic Consultants of Boston
    East Weymouth, Massachusetts 02189, United States
  • Fraser Eye Center
    Fraser, Michigan 48026, United States
  • Kahana Oculoplastic and Orbital Surgery
    Livonia, Michigan 48152, United States
  • Vector Clinical Trials
    Sparks, Nevada 89128, United States
  • Baylor College of Medicine, Alkek Eye Center
    Houston, Texas 77030, United States
  • Neuro Eye Clinical Trials INC
    Houston, Texas 77074, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in May 2026, 10 months.

Of 29 phase 3 interventional studies under Graves Ophthalmopathy, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 25. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Sep 4, 2025
StartActual
Jul 1, 2025
Primary completionActual
May 28, 2026
CompletionActual
May 28, 2026
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07155668
Lead sponsor
Viridian Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 4, 2025
Start date
Jul 1, 2025
Primary completion
May 28, 2026
Completion
May 28, 2026
Last update
Jun 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elegrobart

Start the discussion